ACE2 and asthma: MRx-4DP0004, a strain of the bacterium Bifidobacterium breve in the phylum of Actinobacteria, originally developed for asthma [131], inhibited hyper-inflammatory response by reducing the expression of angiotensin-converting enzyme 2 (ACE2) receptors for maintaining the potential antiviral response [132].